Chronic Liver Disease and Cirrhosis

Chronic liver disease develops when repeated injury causes inflammation and fibrosis over months or years. Cirrhosis is advanced scarring that disrupts normal liver architecture and blood flow. It may remain compensated without obvious complications, but ascites, variceal bleeding, encephalopathy or jaundice mark decompensation and require specialist care.

What the liver does The liver is a large organ in the upper right abdomen with many essential functions. It processes nutrients arriving from the intestine and helps maintain a stable internal environment. It also produces important proteins, makes bile and changes many substances so the body can use or remove them. Metabolism Metabolism describes the chemical processes that build, store and release energy and body materials. The liver stores glucose as glycogen and releases glucose between meals. It processes fats, cholesterol and amino acids from proteins. Liver disease can therefore affect blood glucose, nutrition, muscle mass and lipid handling. Processing medicines and other substances The liver chemically changes many medicines, hormones, alcohol and waste products. These changes can make a substance active, inactive or easier to remove through urine or bile. The popular word detoxification can oversimplify this carefully regulated biological work. A damaged liver may process some medicines more slowly or unpredictably. Protein production The liver makes albumin, which helps keep fluid within the bloodstream and carries several substances. It also makes many proteins involved in immunity, transport and tissue repair. Low albumin can occur in advanced liver disease but also has several non liver causes. Clotting factor production The liver produces many proteins that support blood clotting. It also helps produce proteins that limit excessive clotting. Advanced liver disease can therefore create a complex balance involving both bleeding and thrombosis. An abnormal INR does not describe the complete clotting state in cirrhosis. Bile production The liver makes bile, which helps digest and absorb fats within the small intestine. Bile also carries bilirubin, cholesterol and other substances towards the bowel. Small bile ducts join into larger ducts that drain from the liver. Disease affecting liver cells or bile ducts can cause jaundice and itching. Bilirubin Bilirubin forms mainly when old red blood cells are broken down. The liver processes it and places it into bile for removal. A raised bilirubin can result from liver injury, bile duct obstruction or increased red cell breakdown. Jaundice therefore provides a clue rather than one diagnosis. The liver has substantial reserve A healthy liver can continue many functions despite partial injury. Early chronic liver disease can therefore produce no symptoms and few examination findings. Routine liver blood tests may remain normal despite important fibrosis or cirrhosis. Symptoms often appear only after reserve or blood flow has become significantly affected. What chronic liver disease is Chronic liver disease means persistent liver injury lasting months or years. The injury can involve liver cells, bile ducts, immune reactions, fat accumulation or toxic exposure. Repeated damage activates repair pathways intended to support healing. When injury continues, repair can produce excessive scar tissue called fibrosis. Fibrosis Fibrosis is collagen rich scar tissue laid down within the liver. Early fibrosis can be limited to particular zones around portal tracts or blood vessels. More advanced fibrosis forms bridges between these regions. Treating the cause can slow progression and can sometimes allow partial regression. Cirrhosis Cirrhosis is advanced diffuse fibrosis with regenerative nodules and disrupted liver architecture. Scar tissue divides the liver into abnormal islands of regenerating cells. Blood has greater difficulty passing through the organ. Liver cell function and circulation can both become impaired. Cirrhosis is an advanced stage, not immediate complete failure Cirrhosis is often described as end stage fibrosis because it is the most advanced structural stage. This does not mean that the liver has stopped functioning or that death is imminent. Many people have compensated cirrhosis and remain clinically stable for years. The underlying cause and development of complications strongly influence the course. Fibrosis is not always cirrhosis A person can have mild, moderate or advanced fibrosis without established cirrhosis. These stages still matter because progression can often be slowed. A single abnormal liver blood result cannot determine the fibrosis stage. Compensated cirrhosis Compensated cirrhosis means the liver and circulation still maintain essential function without major decompensation events. The person has not developed clinically significant ascites, variceal bleeding or overt hepatic encephalopathy. They may feel entirely well or report only fatigue and reduced stamina. Surveillance and treatment remain important because complications can develop silently. Decompensated cirrhosis Decompensated cirrhosis means that major complications of cirrhosis have appeared. The principal events are ascites, variceal bleeding, hepatic encephalopathy and clinically significant jaundice. Kidney dysfunction, infection and severe muscle loss commonly accompany decompensation. This is a major clinical turning point requiring specialist assessment. Decompensation can have a trigger Infection, gastrointestinal bleeding, constipation, dehydration and kidney injury can precipitate deterioration. Alcohol related hepatitis, portal vein thrombosis and some medicines can also contribute. Treating the trigger can improve the acute episode. The underlying cirrhosis still requires continuing care. Recompensation Some people improve substantially after the cause is controlled and complications are treated. They may lose ascites and remain free from further encephalopathy or bleeding. Specialists sometimes call sustained improvement recompensation. It does not erase the cirrhosis diagnosis or remove surveillance needs automatically. Causes often overlap Chronic liver disease can have more than one contributor. A person may have metabolic steatotic liver disease and drink enough alcohol to add further injury. Viral hepatitis can coexist with metabolic risk or medicine exposure. The assessment should avoid forcing every case into one simple category. Alcohol related liver disease Regular harmful alcohol exposure can cause fat accumulation, inflammation, fibrosis and cirrhosis. Risk depends on amount, pattern, duration, sex related biology, nutrition and individual susceptibility. Not everyone drinking heavily develops cirrhosis, and cirrhosis does not prove alcohol dependence. The history should be factual and non judgemental. Alcohol cessation Stopping alcohol can prevent further injury and improve outcomes at every stage of alcohol related liver disease. A person who is alcohol dependent can develop dangerous withdrawal if they stop suddenly without support. The plan may require medication, monitoring and specialist alcohol services. Metabolic dysfunction associated steatotic liver disease Metabolic dysfunction associated steatotic liver disease is shortened to MASLD. It involves excess liver fat together with at least one cardiometabolic risk factor. Common associated factors include type 2 diabetes, central obesity, high blood pressure and abnormal blood lipids. Most people with liver fat do not progress to cirrhosis, but fibrosis risk needs assessment. The terminology has changed MASLD replaces the older term non alcoholic fatty liver disease, shortened to NAFLD. The newer name focuses on metabolic drivers and avoids defining a disease only by absence of alcohol. The current published NICE guideline still carries the NAFLD title while its active update adopts MASLD terminology. Older medical records and references may therefore use NAFLD or NASH. Metabolic steatohepatitis Metabolic dysfunction associated steatohepatitis is shortened to MASH. It describes steatotic liver disease with liver cell injury and inflammation. The older term was non alcoholic steatohepatitis, shortened to NASH. Fibrosis stage predicts liver related outcomes more strongly than liver fat alone. Chronic hepatitis B Hepatitis B virus can persist within liver cells and cause long term inflammation. The activity can vary over time, so normal symptoms or one normal blood result do not prove inactivity. Antiviral treatment can suppress viral replication and reduce cirrhosis and cancer risk in eligible people. Specialist monitoring remains important even when the person feels well. Chronic hepatitis C Hepatitis C virus can cause chronic inflammation, fibrosis and cirrhosis over many years. Modern direct acting antiviral treatment cures most infections. Curing the virus reduces future liver risk but may not remove established cirrhosis. People with cirrhosis usually continue specialist surveillance after viral cure. Autoimmune hepatitis Autoimmune hepatitis occurs when the immune system attacks liver cells. It can present suddenly or progress quietly over years. Blood antibodies and immunoglobulins provide clues, while biopsy may support diagnosis. Immunosuppressive treatment can control inflammation and prevent progression in many people. Primary biliary cholangitis Primary biliary cholangitis is shortened to PBC. It is an autoimmune disease damaging small bile ducts within the liver. Fatigue and itching can occur before jaundice or cirrhosis. Disease specific treatment can slow progression, particularly when started before advanced damage. Primary sclerosing cholangitis Primary sclerosing cholangitis is shortened to PSC. It causes inflammation, scarring and narrowing within larger bile ducts. It is associated with inflammatory bowel disease in many people. Specialist care monitors liver damage, bile duct complications and cancer risks. Haemochromatosis Hereditary haemochromatosis increases intestinal iron absorption. Excess iron can accumulate in the liver, pancreas, heart, joints and other tissues. Blood iron studies and genetic testing support diagnosis. Regular removal of blood can prevent or reduce organ injury when used appropriately. Wilson's disease Wilson's disease is an inherited disorder of copper handling. Copper can accumulate within the liver, brain, eyes and other tissues. It often presents in children or younger adults but can be recognised later. Lifelong specialist treatment removes copper or reduces its absorption. Other causes Alpha 1 antitrypsin deficiency can affect the liver and lungs. Long term bile duct obstruction, vascular disorders and selected medicines can cause chronic injury. Some people remain without a fully identified cause despite careful assessment. Early disease is often silent Chronic liver disease and compensated cirrhosis can produce no obvious symptoms. The condition may be found through blood tests, imaging, diabetes review or another investigation. A normal appearance and absence of pain do not exclude advanced fibrosis. Non specific early symptoms Fatigue, reduced appetite, nausea and right upper abdominal discomfort can occur. These symptoms have many possible causes and do not measure fibrosis reliably. Unintentional weight loss and progressive weakness require broader assessment. Signs are clues rather than proof Several examination findings are traditionally associated with chronic liver disease. None confirms cirrhosis alone, and many are absent in compensated disease. Their interpretation depends on symptoms, blood tests, imaging and risk factors. Jaundice Jaundice is yellowing of the whites of the eyes and skin caused by raised bilirubin. It may be less visible on brown or black skin, so the eyes and other features matter. Dark urine and pale stool can accompany impaired bile flow. New jaundice needs prompt assessment because obstruction and acute hepatitis are alternative causes. Spider naevi Spider naevi are small red vessels with fine branches radiating from a central point. They commonly appear on the upper chest, face or arms. Several can occur in cirrhosis because hormone handling and vascular signalling change. A small number can also occur in healthy people or during pregnancy. Palmar erythema Palmar erythema is persistent redness over parts of the palms. It can occur in cirrhosis but also in pregnancy, rheumatoid disease and other conditions. It does not measure liver function or identify the cause. Ascites Ascites is excess fluid within the abdominal cavity. The abdomen can enlarge, feel tense and cause early fullness or breathlessness. Cirrhosis is a common cause, but heart failure, cancer and other diseases can also produce ascites. New ascites usually requires diagnostic fluid sampling. Caput medusae Caput medusae describes enlarged veins radiating across the abdominal wall. It can develop when portal hypertension redirects blood through surface veins. It is an uncommon and non specific sign rather than a required feature of cirrhosis. Splenomegaly Portal hypertension can enlarge the spleen, called splenomegaly. The enlarged spleen can hold more platelets and other blood cells. A falling platelet count can therefore provide an early clue to portal hypertension. Other blood and spleen conditions can cause the same findings. Muscle loss and frailty Cirrhosis can reduce muscle mass through altered metabolism, poor intake and inflammation. This is called sarcopenia when muscle quantity and function are reduced. A person can have obesity and significant muscle loss at the same time. Nutrition and activity support are important parts of treatment. Portal hypertension The portal vein carries blood from the intestines and spleen into the liver. Cirrhotic scar tissue and distorted nodules increase resistance to this flow. Pressure then rises within the portal venous system. This portal hypertension links cirrhosis to varices, ascites, splenomegaly and several other complications. Collateral veins When portal pressure rises, blood seeks alternative routes back to the general circulation. Small veins enlarge into collateral channels around the oesophagus, stomach, rectum and abdominal wall. These veins have thin walls and are not designed for high pressure. Oesophageal and gastric varices Varices are enlarged fragile veins within the oesophagus or stomach. They usually cause no symptoms until they bleed. Medium or large varices can receive preventive treatment with selected beta blockers or endoscopic band ligation. Treatment choice requires specialist assessment and blood pressure monitoring. Variceal bleeding A ruptured varix can cause vomiting of fresh blood or passing black tar like stool. Bleeding may be rapid and life threatening. Emergency treatment includes resuscitation, medicines, antibiotics and urgent endoscopy. This is not managed by waiting for a routine liver appointment. How portal hypertension contributes to ascites High portal pressure pushes fluid from blood vessels into the abdominal cavity. The circulation also responds by retaining sodium and water through the kidneys. Low albumin can add to fluid movement but is not the only mechanism. Spontaneous bacterial peritonitis Spontaneous bacterial peritonitis is shortened to SBP. It is infection of ascitic fluid without an obvious perforated abdominal organ. Possible features include fever, abdominal pain, tenderness, confusion and worsening kidney function. Symptoms can be subtle, so new deterioration in a person with ascites needs urgent assessment. Hepatic encephalopathy Hepatic encephalopathy is altered brain function associated with severe liver dysfunction and portal systemic shunting. The liver and circulation cannot handle some gut derived substances normally. The brain becomes affected through several interacting chemical and inflammatory mechanisms. It is not simply one toxin level and cannot be diagnosed from ammonia alone. Encephalopathy symptoms Early features can include sleep reversal, poor concentration, slowed thinking and personality change. More obvious episodes cause confusion, slurred speech, drowsiness and reduced consciousness. A flapping hand movement called asterixis can occur but is not always present. Stroke, infection, low glucose and medicine effects remain important alternatives. Encephalopathy triggers Common triggers include infection, gastrointestinal bleeding, constipation and dehydration. Kidney injury, electrolyte disturbance and sedating medicines can contribute. Treatment searches for and corrects the trigger while reducing gut derived nitrogen production. Jaundice as decompensation Increasing jaundice can show that liver processing and excretion have worsened. Jaundice with confusion, bleeding, fever or kidney dysfunction is particularly concerning. A blocked bile duct can produce jaundice without cirrhosis and needs a different pathway. Kidney dysfunction Advanced cirrhosis changes circulation and can reduce effective blood flow to the kidneys. Infection, dehydration, bleeding, diuretics and NSAIDs can worsen kidney function. Hepatorenal syndrome is a severe functional kidney failure associated with advanced liver disease. Reduced urine or rapidly rising creatinine requires urgent specialist review. Bruising and bleeding Reduced clotting factor production, low platelets and fragile vessels can increase bleeding. Cirrhosis can also increase thrombosis risk because anticoagulant proteins and blood flow change. Routine clotting tests do not capture this rebalanced haemostasis completely. Routine liver blood tests Common liver blood tests include ALT, AST, alkaline phosphatase, bilirubin and albumin. They measure different aspects of cell injury, bile flow and protein concentration. They are not a direct percentage measure of liver function. NICE advises not using routine liver blood tests to rule out cirrhosis. ALT and AST ALT and AST are enzymes released during cell injury. They can be normal in advanced fibrosis because there may be little active inflammation at that moment. A very high level can occur in acute injury without cirrhosis. Albumin, bilirubin and INR Albumin, bilirubin and INR contribute information about liver reserve and disease severity. Each also has non liver influences. Albumin changes slowly, while bilirubin and INR can worsen during acute decompensation. Ultrasound Ultrasound can show liver texture, nodularity, spleen size, ascites and blood vessel flow. It can identify liver fat and some masses. A normal ultrasound does not reliably exclude early fibrosis or compensated cirrhosis. Non invasive fibrosis assessment Modern pathways increasingly estimate fibrosis risk without routine biopsy. Blood based scores identify people unlikely or more likely to have advanced fibrosis. Elastography then measures liver stiffness more directly. The tests reduce unnecessary biopsy but do not eliminate specialist interpretation. FIB 4 The fibrosis 4 index is shortened to FIB 4. It combines age, AST, ALT and platelet count. A lower result can help rule out advanced fibrosis in an appropriate population. An intermediate or high result prompts further testing rather than confirming cirrhosis. FIB 4 limitations FIB 4 can rise because of age, acute hepatitis or low platelets from another cause. It is less reliable at some age extremes and during acute illness. It should not be calculated as a home diagnostic score or used without the relevant clinical pathway. Enhanced liver fibrosis test The enhanced liver fibrosis test is shortened to ELF. It measures blood markers linked to tissue matrix turnover and fibrosis. The current published NICE fatty liver guideline uses ELF to identify advanced fibrosis. Local pathways may use FIB 4 before ELF or elastography. Transient elastography Transient elastography sends a vibration through the liver and measures how quickly the wave travels. Stiffer tissue generally transmits the wave faster. FibroScan is a commonly used device name for this technique. The measurement is painless and usually completed within minutes. Elastography limitations Inflammation, bile obstruction and liver congestion can increase stiffness without fixed cirrhosis. Obesity and technical factors can reduce measurement reliability. The result therefore needs interpretation with cause, blood tests and imaging. Liver biopsy A liver biopsy removes a small tissue sample for microscopic examination. It can show inflammation, fat, fibrosis and features of particular diseases. Bleeding, pain and sampling limitations mean it is not used routinely when non invasive evidence is sufficient. NICE considers biopsy when elastography is unsuitable or the diagnosis remains uncertain. Investigating the cause Assessment commonly includes hepatitis B and C testing, alcohol history and metabolic risk review. Iron studies, autoimmune antibodies and immunoglobulins can identify less common causes. Age and clinical clues guide testing for Wilson's disease and alpha 1 antitrypsin deficiency. Severity scores The Child Pugh and MELD scores summarise selected laboratory and clinical information. They help estimate risk, guide procedures and support transplant assessment. They do not replace examination or predict an exact outcome for one person. NICE recommends calculating MELD every six months in compensated cirrhosis. Specialist referral NICE recommends referral to hepatology after cirrhosis is diagnosed. Specialists confirm the cause, severity and complication prevention plan. People with decompensation or high complication risk may need a specialist hepatology centre. Screening for varices People with cirrhosis may receive upper gastrointestinal endoscopy to look for oesophageal varices. Current NICE guidance allows a different pathway when carvedilol or propranolol is planned to prevent decompensation. Endoscopy timing and preventive treatment are specialist decisions. Preventing first decompensation NICE now considers carvedilol first choice for selected compensated cirrhosis with clinically significant portal hypertension. Propranolol is an alternative when carvedilol is contraindicated. These medicines can lower heart rate and blood pressure significantly in cirrhosis. They require low starting doses and monitored adjustment. Hepatocellular carcinoma Hepatocellular carcinoma is the main primary cancer arising from liver cells and is shortened to HCC. Cirrhosis is an important risk factor regardless of the original cause. The cancer can remain asymptomatic until advanced. Surveillance aims to detect smaller tumours when treatment options are broader. HCC surveillance For cirrhosis without chronic hepatitis B, NICE offers liver ultrasound every six months when surveillance remains appropriate. Serum alpha fetoprotein may be measured with the scan. People with chronic hepatitis B follow the relevant HBV surveillance pathway. Surveillance reduces risk through earlier detection but cannot prevent every cancer or guarantee diagnosis. Treating the underlying cause Cause directed treatment is central even after cirrhosis has formed. Alcohol cessation, viral suppression or cure, immune treatment and removal of excess iron or copper can slow further injury. Metabolic care addresses weight, diabetes, blood pressure and cardiovascular risk. MASLD management principles Sustained weight reduction can reduce liver fat and inflammation where excess weight contributes. Regular physical activity benefits the liver and cardiovascular system even without major weight loss. Diabetes, blood pressure and lipids require evidence based treatment. Statins are generally continued when indicated rather than stopped because of stable MASLD alone. Avoiding further alcohol exposure People with cirrhosis are usually advised to avoid alcohol because remaining liver reserve is limited. The plan must include withdrawal safety when dependence is possible. Support can involve primary care, alcohol services, psychology and peer support. Medicine and supplement review Every prescribed, over the counter and herbal product should be reviewed. NSAIDs can worsen kidney function, fluid retention and bleeding risk in cirrhosis. Sedatives and opioids can contribute to confusion and constipation. Some herbal and bodybuilding products can directly injure the liver. Paracetamol requires individual advice Paracetamol is not automatically forbidden in chronic liver disease. Dose, alcohol use, nutrition and other medicines determine safe prescribing. The person should follow clinician or pharmacist advice and avoid combining products containing paracetamol unknowingly. Vaccination UK immunisation guidance includes influenza and pneumococcal vaccination for chronic liver disease. Hepatitis A and hepatitis B vaccination are also recommended for severe chronic liver disease when immunity is absent. COVID 19 and other vaccines follow the current national eligibility schedule. Nutrition Cirrhosis can cause malnutrition even when body weight appears high because ascites and obesity can hide muscle loss. Regular meals and adequate protein generally support muscle maintenance. Long fasting periods can worsen muscle breakdown. Dietary advice should be individualised rather than based on unnecessary protein restriction. Salt and fluid People with ascites commonly receive advice to avoid excessive dietary salt. Severe restriction can reduce food intake and must be balanced against nutrition. Fluid restriction is not required for everyone with cirrhosis and should follow specialist advice. Treating ascites Specialists use diuretic medicines to increase sodium and water removal in selected people. Large or tense ascites may require drainage called paracentesis, often with albumin replacement. Refractory ascites can lead to consideration of a TIPS procedure or transplantation. Treating hepatic encephalopathy Treatment identifies infection, bleeding, constipation, dehydration and medicines that triggered the episode. Lactulose is commonly used to alter bowel contents and increase stool passage. Rifaximin can reduce recurrence in selected people. These medicines require an individual specialist plan. Preventing spontaneous bacterial peritonitis NICE does not recommend routine preventive antibiotics for everyone with cirrhosis and ascites. They are considered only for selected people at high risk or when infection would seriously disrupt treatment. Unnecessary prolonged antibiotics can cause adverse effects and resistance. Transjugular intrahepatic portosystemic stent A transjugular intrahepatic portosystemic stent is usually shortened to TIPS or TIPSS. It creates a channel within the liver that reduces portal pressure. It can treat selected refractory ascites or uncontrolled variceal bleeding. It can also worsen hepatic encephalopathy and requires careful selection. Liver transplantation Transplantation replaces the diseased liver with a donor organ. It is considered for selected people with decompensation, poor predicted survival or particular liver cancers. Assessment includes physical health, cause treatment, nutrition, substance use and social support. Early referral allows evaluation before the person becomes too unwell. Prognosis The outlook varies with the cause, fibrosis severity and development of decompensation. Many people with compensated cirrhosis remain stable for years with treatment and surveillance. Decompensation increases health risks but can improve when triggers and the underlying cause are controlled. Population averages cannot predict one person's exact course. Living with cirrhosis Regular appointments can include blood tests, ultrasound, medicine review and variceal assessment. The person and family should know how to recognise bleeding, confusion, infection and rapidly increasing fluid. Care should support work, nutrition, mental wellbeing and alcohol or metabolic treatment without blame. What this lesson should not be used for This lesson cannot diagnose cirrhosis from fatigue, jaundice, a blood test or one ultrasound phrase. Do not calculate FIB 4 as a home diagnosis or stop important medicines independently. Do not treat new confusion as ordinary tiredness in a person with liver disease. Do not wait for routine review after vomiting blood, black stool, fever with ascites or rapidly worsening jaundice. Call 999 for major bleeding, severe confusion, collapse or another life threatening deterioration.

Chronic liver injury can progress through fibrosis to cirrhosis, which disrupts liver architecture and portal blood flow. Compensated cirrhosis may remain silent, while ascites, variceal bleeding, hepatic encephalopathy or jaundice mark decompensation. Non invasive fibrosis tests support earlier diagnosis, and treatment targets the cause while preventing complications and liver cancer.